Molecular diagnosis of glycogen storage disease type IX using a glycogen storage disease gene panel.
Glycogen storage disease
Hepatocellular carcinoma
PHKA2
PHKG2
Phosphorylase kinase
Journal
European journal of medical genetics
ISSN: 1878-0849
Titre abrégé: Eur J Med Genet
Pays: Netherlands
ID NLM: 101247089
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
16
08
2019
revised:
20
03
2020
accepted:
28
03
2020
pubmed:
4
4
2020
medline:
30
12
2020
entrez:
4
4
2020
Statut:
ppublish
Résumé
Glycogen storage disease type IX (GSD IX) is caused by a deficiency of hepatic phosphorylase kinase. The aim of this study was to clarify the clinical features, long term outcomes, and genetic analysis of GSD IX in Korea. A GSD gene panel was created and hybridization capture-based next-generation sequencing was performed. We investigated clinical laboratory data, results of molecular genetic analysis, liver biopsy findings, and long-term outcomes. Ten children were diagnosed with GSD IX at Seoul National University Children's Hospital. Hypoglycemia, hyperlactacidemia, hypertriglyceridemia, hyperuricemia, liver fibrosis on liver biopsy, and short stature was found in 30%, 56%, 100%, 60%, 80% and 50% of the children, respectively. Seven PHKA2 variants were identified in eight children with GSD IXa-one nonsense (c.2268dupT; p.(Asp757Ter)), two splicing (c.918+1G > A, c.718-2A > G), one frameshift (c.405_419delinsTCCTGGCC; p.(Asp136ProfsTer11)), and three missense variants (c.3628G > A; p.(Gly1210Arg), c.1245G > T and c.2746C > T; p.(Arg916Trp)). Two variants of PHKG2 were identified in two children with GSD IXc-one frameshift (c.783delC; p.(Ser262AlafsTer6)) and one missense (c.661G > A; p.(Val221Met)). Elevated liver enzymes and hypertriglyceridemia in children with GSD IXa tended to improve with age. For the first time, we report hepatocellular carcinoma in a patient with GSD IXc. The GSD gene panel is a useful diagnostic tool to confirm GSD IX. The clinical phenotype of GSD IXc is severe and monitoring for the development of hepatocellular carcinoma should be implemented.
Identifiants
pubmed: 32244026
pii: S1769-7212(19)30557-9
doi: 10.1016/j.ejmg.2020.103921
pii:
doi:
Substances chimiques
PHKA2 protein, human
EC 2.7.1.19
Phosphorylase Kinase
EC 2.7.1.19
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
103921Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest Authors have no relevant financial relationships to disclose or conflicts of interest.